Mochi Health Alternatives: Best Options for Every GLP-1 Use Case

What Mochi Health Actually Offers (and Where It Falls Short)

Mochi Health positions itself as a full-spectrum obesity-medicine practice delivered online. Its headline value is insurance billing: unlike most GLP-1 telehealth startups, Mochi attempts prior authorizations on your behalf for brand-name drugs like Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide). For patients whose insurance covers these drugs, that can mean near-zero out-of-pocket cost.

The Insurance Billing Model

When prior authorization succeeds, the effective monthly cost drops dramatically. Novo Nordisk lists Wegovy at roughly $1,349 per month, but commercially insured patients with a successful PA can pay as little as $0, $25 using manufacturer savings cards alongside insurance coverage. Mochi's in-house PA team handles appeals, which competitors often skip entirely.

The tradeoff is time. PA denials and appeals can take four to eight weeks. Patients who need to start treatment immediately frequently turn to compounded semaglutide as a bridge.

The Compounded Semaglutide Question

Mochi also prescribes compounded semaglutide through 503A and 503B pharmacies for cash-pay patients, typically priced in the $130, $299/month range. In March 2025, the FDA removed semaglutide from its drug shortage list, which means 503A pharmacies may no longer legally compound copies of Wegovy or Ozempic under shortage authority. Mochi and every competitor must manage that regulatory shift. FDA shortage list status should be confirmed directly with your provider at the time of prescribing.

Tirzepatide remains on the FDA shortage list as of mid-2025, so compounded tirzepatide remains legally available from qualifying pharmacies for now.

Where Mochi Underperforms

Three consistent limitations appear in patient reviews and independent analysis:

1. Coaching depth varies by tier. The base plan lacks synchronous dietitian sessions; that feature requires upgrading to a higher-cost tier.
2. Provider continuity is inconsistent. Some patients report seeing a different clinician at each visit rather than a dedicated prescriber.
3. Breadth is limited. Mochi does not currently offer testosterone replacement therapy (TRT) or female HRT as standalone programs, which matters if you want a single platform for hormonal and metabolic care.

How GLP-1 Drugs Actually Perform: The Evidence Base

Before comparing platforms, the clinical effect size matters. Platforms vary in execution; the drugs themselves have well-characterized efficacy data.

Semaglutide (Wegovy) Evidence

In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean weight loss of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001) in adults with a BMI <30 plus at least one weight-related comorbidity, or BMI <27 without comorbidity exclusion. [1] The SELECT cardiovascular outcomes trial (N=17,604) then showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in people with established CVD and overweight or obesity, without a diabetes diagnosis at baseline. [2]

Tirzepatide (Zepbound) Evidence

SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced 20.9% mean body-weight reduction at 72 weeks versus 3.1% placebo (P<0.001). [3] The dual GIP and GLP-1 agonism appears to add meaningful efficacy above semaglutide in head-to-head analyses, though no dedicated non-inferiority RCT has been published as of mid-2025.

The Endocrine Society 2023 Obesity Pharmacotherapy Guidelines state: "Pharmacological therapy for obesity should be considered for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity, when lifestyle intervention alone has not achieved sufficient weight loss." [4]

The Six Best Mochi Health Alternatives by Use Case

Not every patient has the same priority. Below, each alternative is matched to the scenario where it most outperforms Mochi.

Best for Brand-Name GLP-1 With Insurance: Calibrate

Calibrate combines insurance-covered GLP-1 prescribing with a structured one-year metabolic reset program that includes synchronous video visits and a dedicated health coach. The program cost is $1,599/year for coaching, separate from medication cost billed to insurance.

Calibrate's model suits patients who have commercial insurance likely to cover GLP-1 drugs and want a formal structured program rather than an a-la-carte approach. The company has published internal outcome data showing roughly 15% mean weight loss at 12 months in a real-world cohort, consistent with STEP-1 data.

One limitation: Calibrate does not prescribe compounded peptides, so patients whose PA is denied face a gap in access until an appeal resolves.

Best for Lowest Cash Price on Compounded Tirzepatide: Hims & Hers (Hers Weight Loss)

Hims & Hers entered the compounded tirzepatide market aggressively and currently prices compounded tirzepatide at approximately $199/month for a maintenance dose, with an introductory offer at $149 for the first month. That undercuts Mochi's cash-pay pricing on the same molecule.

The platform does not handle insurance billing at all. Patients who expect insurance to eventually cover their medication may find it frustrating to pay out of pocket without a concurrent PA attempt.

The HealthRX GLP-1 Platform Selection Framework below (to be illustrated by the design team) maps five decision variables, including insurance status, preferred molecule, desired coaching depth, hormone co-management needs, and budget, against six major platforms. Use it during your initial consultation with a HealthRX provider to identify your best starting point.

Best for Compounded Semaglutide With Clinical Oversight: Found

Found (formerly Kickstarter Health) prescribes both GLP-1 drugs and non-GLP-1 options such as bupropion-naltrexone and metformin. The monthly membership is $99, and compounded semaglutide runs approximately $149, $199/month on top of that.

Found's distinguishing feature is prescribing breadth. Patients who are not GLP-1 candidates, either due to contraindications such as personal or family history of medullary thyroid carcinoma or MEN2, or due to cost, can receive an alternative pharmacological protocol without switching platforms. [5]

Best for TRT Plus Metabolic Care on One Platform: Maximus or Fountain TRT

Mochi does not offer TRT. For men who want GLP-1 therapy and testosterone optimization managed together, either Maximus or Fountain TRT fills that gap. Both platforms prescribe compounded testosterone cypionate, anastrozole when indicated, and have expanded GLP-1 offerings as of 2024.

Testosterone deficiency and obesity share a bidirectional relationship: low testosterone raises visceral fat, and visceral fat suppresses luteinizing hormone-driven testosterone production. [6] Managing both simultaneously may produce better metabolic outcomes than treating each in isolation, though no large RCT has tested a combined telehealth protocol specifically.

Best for Women Needing HRT and GLP-1 Together: Alloy or Midi Health

Mochi's gap for female hormonal health is meaningful. Postmenopausal women frequently seek weight-loss support alongside estrogen or progesterone therapy. Alloy focuses on menopause hormone therapy and has added GLP-1 prescribing; Midi Health offers a similar combined model with board-certified menopause specialists.

The Menopause Society (formerly NAMS) 2023 position statement on hormone therapy notes that "for most healthy symptomatic women who are within 10 years of menopause or younger than age 60, the benefits of hormone therapy outweigh the risks." [7] Pairing that with GLP-1 therapy through one provider reduces care fragmentation.

Best for Highest-Touch Coaching and Behavior Change: WeightWatchers Clinic (WW Clinic)

WW Clinic (formerly Sequence) merges the WW behavior-change infrastructure with clinical GLP-1 prescribing. Patients get access to the WW app, community, and food-tracking tools alongside a prescribing provider. The membership costs roughly $99, $129/month, with medication costs separate.

For patients whose primary obstacle to weight-loss maintenance is behavioral rather than pharmacological, the coaching density here exceeds what Mochi offers at a comparable price tier.

Head-to-Head Comparison: Mochi vs. Top Alternatives

| Platform | Insurance Billing | Compounded GLP-1 | TRT / HRT | Coaching Included | Est. Monthly Cost (Cash, Drug Included) | |---|---|---|---|---|---| | Mochi Health | Yes | Yes | No | Limited | $130, $399 | | Calibrate | Yes | No | No | Yes (structured) | $133 + medication | | Hims & Hers | No | Yes | Hims only (TRT) | No | $149, $199 | | Found | No | Yes | No | Yes | $248, $298 | | Maximus / Fountain | No | Yes (TRT + GLP-1) | Yes (TRT) | Limited | $199, $349 | | Alloy / Midi | Limited | Some | Yes (HRT) | Yes | $200, $350 | | WW Clinic | Some | Yes | No | Yes (extensive) | $228, $329 |

Costs are estimates based on publicly listed pricing as of July 2025 and will change. Verify current pricing directly with each platform before enrolling.

Is Mochi Health Legit? A Clinical Assessment

Mochi Health is a legitimate medical practice. Its providers operate under state medical licenses, prescriptions are issued through licensed pharmacies, and the company accepts and bills major insurance carriers. None of that is common among direct-to-consumer GLP-1 startups, most of which are cash-only and never attempt prior authorization.

Regulatory Standing

The platform operates within the telemedicine prescribing framework governed by the Ryan Haight Online Pharmacy Consumer Protection Act and DEA telehealth rules. Controlled substances (such as phentermine, which Mochi occasionally prescribes) require compliance with additional DEA scheduling rules. Mochi's pharmacy partners are licensed in the states where they dispense.

Clinical Quality

Obesity medicine is a board-certified specialty through the American Board of Obesity Medicine (ABOM). Mochi states that its clinical team includes ABOM-certified providers, though not every prescriber a patient sees carries that credential. Asking at intake whether your assigned provider is ABOM-certified is reasonable.

The American Board of Obesity Medicine defines obesity as "a complex, chronic, relapsing, neurobiological disease, in which increases in body fat promote adipose tissue dysfunction and abnormal fat-mass physical forces that result in metabolic and psychosocial health complications." [8] A platform whose clinical team understands that framework prescribes differently from one that treats obesity as a simple calorie deficit problem.

Patient Reviews: Signal vs. Noise

Aggregated reviews on Trustpilot and Google reflect a bimodal distribution: patients who got insurance coverage love the platform; patients who faced repeated PA denials or experienced inconsistent provider assignments report frustration. That pattern is consistent with the structural limitations noted above and not unique to Mochi.

Choosing Between Compounded and Brand-Name GLP-1

The compounding question deserves specific attention because it affects every platform comparison.

Pharmacokinetic Equivalence

FDA-approved semaglutide (Ozempic, Wegovy) uses a specific salt form and a proprietary injection device. Compounded semaglutide uses semaglutide base (free acid form) or sodium salt, mixed at a 503A or 503B pharmacy. No published RCT has directly compared compounded semaglutide to brand Wegovy for efficacy or safety in a head-to-head trial. The FDA's own guidance states it "cannot assure the safety, effectiveness, or quality" of compounded versions. [9]

Compounded products are prepared from pharmaceutical-grade active pharmaceutical ingredient (API), and many obesity medicine physicians accept them as a reasonable interim option when brand-name drugs are inaccessible due to cost or shortage.

The March 2025 Shortage-List Removal

The FDA removed semaglutide from the drug shortage list in March 2025 after determining adequate supply exists for both Wegovy and Ozempic. [9] This means 503A pharmacies cannot continue to compound copies under shortage authority after the FDA's grace-period deadline. Platforms that built their business on compounded semaglutide, including Mochi, face a structural shift.

Tirzepatide remains on the shortage list, so compounded tirzepatide continues under that authority for the time being. Patients starting treatment after July 2025 should confirm the current legal status of any compounded GLP-1 they are prescribed before their first injection.

Cost Breakdown: What You Will Actually Pay

With Good Insurance

If your commercial insurance covers Wegovy and you have a BMI of 30 kg/m² or a BMI of 27 kg/m² plus a qualifying comorbidity such as hypertension or type 2 diabetes, a successful PA through Mochi or Calibrate could reduce your cost to $0, $25/month using the Novo Nordisk savings card alongside insurance.

Without Insurance or With a Denied PA

| Option | Estimated Monthly Cost | Drug | |---|---|---| | Brand Wegovy (cash) | $1,349 | Semaglutide 2.4 mg | | Brand Zepbound (cash) | $1,059 | Tirzepatide up to 15 mg | | Compounded semaglutide (503B) | $130, $250 | Semaglutide base/salt | | Compounded tirzepatide (503B) | $149, $299 | Tirzepatide | | Oral semaglutide Rybelsus (7 mg) | $935 (list) | Semaglutide oral |

Rybelsus achieves roughly 5 to 8% weight loss at 26 weeks in type 2 diabetes trials, which is meaningfully less than injectable Wegovy at equivalent duration. [10] It is not FDA-approved for weight management but is sometimes prescribed off-label when injections are not acceptable to the patient.

Clinical Decision Pathway: Which Platform Fits Which Patient

The following scenarios cover the most common patient profiles arriving at a GLP-1 telehealth platform.

You have commercial insurance and a BMI of 30 kg/m² or higher. Start with Mochi or Calibrate. Both attempt prior authorization for brand-name GLP-1. The expected wait for PA resolution is two to six weeks.

You want to start treatment this week and will pay cash. Hims & Hers or Found can onboard you within 48 hours and ship compounded tirzepatide without an insurance step. Confirm the current compounding legal status before committing.

You are a man with low testosterone and excess weight. Mochi cannot serve you on both fronts. Maximus or Fountain TRT, both of which now prescribe GLP-1 drugs, let you consolidate labs, prescriptions, and follow-up visits.

You are perimenopausal or postmenopausal and need both GLP-1 and HRT. Alloy or Midi Health offer the only integrated model. Fragmented care, where an OB-GYN manages HRT and a separate telehealth app manages GLP-1 drugs, increases the chance of drug interaction oversight failures.

You have struggled with binge eating or emotional eating driving your weight regain. WW Clinic's behavioral infrastructure adds tools that no pure-prescribing platform provides. The combination of naltrexone-bupropion (Contrave) plus behavioral coaching may outperform GLP-1 alone in patients with significant behavioral drivers, though head-to-head RCT data are limited.